Bli medlem
Bli medlem

Du är här

2020-06-11

RhoVac recruits Professor Emeritus Per-Anders Abrahamsson and Professor Klaus Brasso to its scientific advice board

Per-Anders-Abrahamsson is former Head of Operations at the Urological Clinic, Skåne University Hospital SUS and Research Group Head at the Faculty of Medicine, Department of Clinical Sciences, at Lund University. In these capacities, during the years 1998-2015, he led the development of the urology operations in Malmö and Lund to become one of Sweden's finest. Professor Abrahamsson has published over 300 scientific articles and authored 80 book chapters in urology, focusing on diseases of the prostate. He is an adviser to the editors of a number of scientific journals and is often invited as a speaker at international congresses, appearances that have been awarded with numerous awards. Professor Abrahamsson has also been Secretary General of the European Association of Urology (EAU), and is an adjunct professor at the Department of Urology at the University of Rochester Medical Center, New York, USA, and at the Russian Institute of Urology, Moscow, Russia. Professor Abrahamsson is currently Chief Physician at the Peritus Clinic at Medicon Village in Lund.

Klaus Brasso, graduated in 1985 at the University of Copenhagen, Denmark, and in 2000 he obtained his doctorate at the same university. Professor Brasso is active in the Department of Clinical Medicine at the University of Copenhagen and is also a member of the management of the Copenhagen Prostate Cancer Center (CPC) at Rigshospitalet in Copenhagen. CPC is a center for most research activities on prostate cancer screening and treatment - from basic prostate cancer research, to the testing of new drugs and treatment methods. Professor Brasso  who has published more than 200 scientific articles, has also a long and solid experience in clinical studies in urology, from clinical phase I to phase III studies, and he is the Principle Investigator in RhoVac's ongoing clinical phase IIb study in prostate cancer (BraVac) which is expected to recruit 180 patients in Europe and the United States.

CEO Anders Månsson comments: "I am very pleased that we have succeeded in recruiting such prominent names in international urology as Professors Abrahamsson and Brasso. In addition to the scientific advice they can offer, this recruitment also generates great credibility and attention around our RV001 project and the company, and that will benefit our partnering process going forward."

Författare RhoVac

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.